It was found to be safe and well tolerated and cancer patients are currently part of or being recruited for eight other phase I/phase II studies, which will evaluate treatment combinations of immunotherapy or radiotherapy with HuMax-IL8 after successful in vivo studies (Table 3) [117, 201]. This evidence concerns the gene CXCL8 and cancer.